NLY101 May Block Progression of Parkinsons!

Jul 8, 2018 | Parkinson Disease

Pre-clinical (mice study) recently published in Nature, Johns Hopkins researchers may be on to a drug that now only slows the progression of Parkinson’s disease but also reduces symptoms.

The study, driven by Ted Dawson, director of The Institute for Cell Engineering and professor of neurology Johns Hopkins University School of Medicine.

Researchers noted that after they performed experiments with human brain cell cultures and live mouse models they observed the drug, NLY01, “blocked the degradation of brain cells that is the hallmark of Parkinson’s disease.” The drug will move to clinical trials in 2018.  If clinical trials are successful for NLY101 it would be one of the first treatments to directly target progression of Parkinson’s disease.

Study results were recently published in Nature

The compound’s developer is both Johns Hopkins and Neuraly, a tenant and participant in Biohealth Innovation

Neuraly founders and equity holders include Dr. Dawson and Dr. Hak Seo Ko

Dr. Dawson:

Dr. Ko:

View article here

Source: HUB JHU


Pin It on Pinterest